No Data
No Data
No Data
No Data
No Data
ENTHEON BIOMEDICAL CORP To Carry Out 1-for-10 Reverse Stock Split On March 1st, 2024
February 29th - $ENTHEON BIOMEDICAL CORP(ENTBF.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from March 1st, 2024.$ENTHEO
moomoo NewsFeb 28 19:40 ET
RBC Downgrades Nevro to Sector Perform, Cites Salesforce Turnaround
Seeking AlphaJan 12 11:01 ET
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. Numinus (OTC:NUMIF) concluded its acquisition of Novamind (OTC
Benzinga Real-time NewsJun 15, 2022 12:34 ET
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Cybin Inc. (NEO:CYBN) (NYSE:CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine ("DMT") study from
Benzinga Real-time NewsJun 7, 2022 17:10 ET
Cybin to acquire DMT clinical study from Entheon Biomedical
Cybin (NYSE:CYBN) added ~8% in the pre-market Tuesday after the psychedelics-focused biopharma announced that its subsidiary Cybin IRL Limited agreed to acquire a Phase 1 N,N-dimethyltryptamine ("DMT"
Seeking AlphaJun 7, 2022 08:28 ET
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC:EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treat
Benzinga Real-time NewsJun 1, 2022 16:30 ET
No Data
No Data